Patents by Inventor Valerie Odegard

Valerie Odegard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220249685
    Abstract: Anti-mesothelin antibodies and conjugates comprising such antibodies are disclosed herein as well as the use of such conjugates in the treatment of disease, such as cancer.
    Type: Application
    Filed: June 18, 2020
    Publication date: August 11, 2022
    Inventors: Brenda STEVENS, Peter Robert BAUM, Robert DUBOSE, Valerie ODEGARD
  • Publication number: 20220105196
    Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.
    Type: Application
    Filed: October 4, 2021
    Publication date: April 7, 2022
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
  • Patent number: 11179473
    Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: November 23, 2021
    Assignee: Silverback Therapeutics, Inc.
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
  • Publication number: 20210275683
    Abstract: The present disclosure provides conjugates of anti-Nectin-4 antibodies or antigen binding fragments thereof to a myeloid cell agonist, compositions comprising the conjugates, and methods of treating cancer with the conjugates. The present disclosure also provides for anti-Nectin-4 antibodies or antigen binding fragments thereof and method for using the antibodies or antigen binding fragments thereof in treating cancer.
    Type: Application
    Filed: February 19, 2021
    Publication date: September 9, 2021
    Inventors: Peter R. Baum, Robert Dubose, Valerie Odegard, Brenda Stevens, Philip Tan
  • Publication number: 20210154317
    Abstract: Various compositions are disclosed for the treatment of viral infections. The compositions of conjugates comprise antibody constructs attached to myeloid cell agonists via a linker are also provided. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating viral infections, such as viral liver diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: May 27, 2021
    Inventors: Peter Armstrong Thompson, Valerie Odegard, Robert Finley Dubose, Sean Wesley Smith, Craig Alan Coburn
  • Publication number: 20210130473
    Abstract: Various conjugates and compositions thereof are disclosed for use in the treatment of a liver disease, such as liver cancer and liver fibrosis. The compositions comprise conjugates, wherein the conjugates are comprised of an antibody or antibody construct specific for ASGR1 or ASGR2 attached to a TGF?R1 inhibitor via a linker. Additionally provided are the methods of preparation of the conjugates and compositions thereof.
    Type: Application
    Filed: October 9, 2020
    Publication date: May 6, 2021
    Inventors: Peter R. BAUM, Robert DUBOSE, Valerie ODEGARD, Philip TAN, Peter A. THOMPSON, Sean W. SMITH, Brenda STEVENS
  • Publication number: 20210115109
    Abstract: Various compositions are disclosed. The compositions of conjugates comprising immune-modulatory agents are also provided. Additionally provided are the methods of preparation and use of the conjugates. This includes methods for treating disorders, such as cancer and fibrosis.
    Type: Application
    Filed: April 23, 2020
    Publication date: April 22, 2021
    Inventors: Peter Armstrong Thompson, Robert Finley Dubose, Peter Robert Baum, Valerie Odegard
  • Publication number: 20200199247
    Abstract: Antibody conjugates of immune-modulatory compounds and pharmaceutical compositions for use in the treatment of disease, such as fibrotic diseases, autoimmune, or autoinflammatory diseases, are disclosed herein. The disclosed conjugates are useful, among other things, in treating fibrotic diseases, autoimmune diseases, or autoinflammatory diseases, such as by modulating TGF?R1, TGF?R2, TNKS, TNIK, or mTOR.
    Type: Application
    Filed: June 7, 2018
    Publication date: June 25, 2020
    Inventors: Peter Armstrong THOMPSON, Badreddin EDRIS, Craig Alan COBURN, Peter Robert BAUM, Valerie ODEGARD
  • Publication number: 20200191774
    Abstract: Provided herein are methods, compositions and articles of manufacture for use in connection with cell therapy involving the administration of one or more doses of a therapeutic T cell composition. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the provided embodiments, including the numbers of cells or units of cells administered and/or the potency of administered cells, provide various advantages, such as lower risk of toxicity in subjects administered the T cell compositions.
    Type: Application
    Filed: February 27, 2018
    Publication date: June 18, 2020
    Applicant: Juno Therapeutics, Inc.
    Inventors: Brian CHRISTIN, Michael Gerard COVINGTON, Kedar Himanshu DAVE, Richard James GETTO, Jr., Tom KOWSKI, Ryan P. LARSON, Christopher Glen RAMSBORG, Nikolaus Sebastian TREDE, Clinton WEBER, James Boyd WHITMORE, Nathan YEE, Pascal BEAUCHESNE, Travis BECKETT, Samuel Charles BLACKMAN, Nathaniel CHARTRAND, Mel DAVIS-PICKETT, Mark GILBERT, Nathaniel LAMBERT, He LI, Mary MALLANEY, Kathryn Lindsay POLLOCK, Valerie ODEGARD, Jeff SMITH, Claire SUTHERLAND, Andrew W. WALKER
  • Publication number: 20200113912
    Abstract: Methods and conjugates are disclosed for alleviating toxicity(ies) associated with administration of immune-stimulatory conjugates, and in particular for alleviating toxicity(ies) associated with intravenous administration of such conjugates.
    Type: Application
    Filed: September 11, 2019
    Publication date: April 16, 2020
    Applicant: Silverback Therapeutics, Inc.
    Inventors: Valerie Odegard, Peter Baum, Sean Wesley Smith, Craig Alan Coburn, Peter Armstrong Thompson
  • Publication number: 20180319862
    Abstract: Provided are chimeric receptors for engineering cells for adoptive therapy, including T cells, and the genetically engineered cells. In some aspects, also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and method for their administration to subjects. In some embodiments, the cells, such as T cells, contain genetically engineered antigen receptors that specifically bind to antigens, such as a chimeric antigen receptor (CAR), and which contain an intracellular signaling domain capable of inducing TRAF6-mediated signaling. In some embodiments, features of the cells and methods provide for increased or improved activity, efficacy and/or persistence.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 8, 2018
    Applicant: Juno Therapeutics, Inc.
    Inventors: Lucas James THOMPSON, Valerie ODEGARD, Blythe SATHER, Archana BRAHMANDAM
  • Publication number: 20180161368
    Abstract: Provided are engineered cells for adoptive therapy, including T cells. Also provided are methods and compositions for engineering and producing the cells, compositions containing the cells, and method for their administration to subjects. In some embodiments, the cells, such as T cells, contain genetically engineered antigen receptors that specifically bind to antigens, such as a chimeric antigen receptor (CAR). In some embodiments, the cells, such as a CAR-expressing T cell, contains an agent that is capable of reducing an inhibitory effect by repressing and/or disrupting a gene in an engineered cell, such as a gene involved in inhibiting the immune response. In some embodiments, features of the cells and methods provide for increased or improved activity, efficacy and/or persistence.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 14, 2018
    Applicant: Juno Therapeutics, Inc.
    Inventor: Valerie ODEGARD
  • Publication number: 20170008960
    Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.
    Type: Application
    Filed: February 10, 2016
    Publication date: January 12, 2017
    Inventors: Valerie Odegard, Catherine J. McMahan, Peter Robert Baum, Peter Armstrong Thompson, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan
  • Publication number: 20110217302
    Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.
    Type: Application
    Filed: October 9, 2009
    Publication date: September 8, 2011
    Applicant: Emergent Product Development Seattle, LLC
    Inventors: Valerie Odegard, Catherine J. McMahan, Peter Robert Baum, Peter Armstrong Thompson, Philip Tan, John W. Blankenship, Sateesh Kumar Natarajan